Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSR591813L · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| SSR591813L (dianicline) | DRUG | - |
Inclusion Criteria: * Outpatients, over legal age, smoking at least 10 cigarettes/day as a mean within the 2 months preceding the screening visit. Exclusion Criteria: * Patients who have taken an investigational drug within the past six months prior to the screening visit. * Patients who had a pr...
SSR591813L, also known as dianicline, is an investigational small molecule being developed for smoking cessation. It is intended to help cigarette smokers quit smoking. The drug is in Phase 3 clinical development, though the pivotal trial has been completed.
SSR591813L targets nicotinic acetylcholine receptors. As a partial agonist, it is designed to reduce the rewarding effects of nicotine and alleviate withdrawal symptoms, thereby aiding smoking cessation. This mechanism is intended to help smokers quit by decreasing cravings and the satisfaction from smoking.
SSR591813L is being developed by Sanofi, a global pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is responsible for the clinical development and potential commercialization of this investigational drug for smoking cessation.
SSR591813L is in Phase 3 clinical development. The Phase 3 trial, known as AMERIDIAN, has been completed. However, the drug remains investigational and has not been approved by regulatory authorities. Its safety and efficacy are still being evaluated.
SSR591813L has one completed Phase 3 clinical trial, NCT00387946, titled 'Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)'. This randomized, double-blind trial enrolled 630 participants in the United States and Canada, but it was uncontrolled, meaning there was no placebo or active comparator.
Yes, SSR591813L is the same as dianicline. The drug is known by both names, with dianicline being the generic name used in clinical trial documentation. Researchers and investors may encounter either name when reviewing data on this smoking cessation candidate.